Guardant Health, Inc. (GH)
| Market Cap | 4.71B |
| Revenue (ttm) | 391.09M |
| Net Income (ttm) | -419.24M |
| Shares Out | 101.92M |
| EPS (ttm) | -4.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,036,741 |
| Open | 44.76 |
| Previous Close | 44.46 |
| Day's Range | 44.01 - 46.27 |
| 52-Week Range | 27.65 - 133.82 |
| Beta | 0.72 |
| Analysts | Buy |
| Price Target | 120.08 (+159.6%) |
| Earnings Date | Aug 4, 2022 |
About GH
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect... [Read more...]
Financial Performance
In 2021, GH's revenue was $373.65 million, an increase of 30.32% compared to the previous year's $286.73 million. Losses were -$405.67 million, 59.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for GH stock is "Buy." The 12-month stock price forecast is 120.08, which is an increase of 159.63% from the latest price.
News
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it has purchased the remaining shares of Guardant Health AMEA, Inc., held by ...
Why Shares of Guardant Health Dropped 33.6% in May
The biotech company is down more than 61% this year.
Guardant Health to Participate in Upcoming June Investor Conferences
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. ...
First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d'Hebron Institute of Oncology
PALO ALTO, Calif. & BARCELONA, Spain--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Vall d'Hebron Institute of Oncology (VHIO), one of Europe's leadi...
Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at 2022 American Society of Clinical Onco...
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it will present new data at the 2022 American Society of Clinical Oncology (...
Guardant Health Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-of-its Kind Pro...
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced data showing its blood-based multimodal test achieved clinically significant...
Why Guardant Health Stock Is Crashing Today
Investors reacted negatively after the company's Q1 update.
Guardant Health Clocks 22% Jump In Q1 Revenues, Reiterates FY22 Guidance
Guardant Health Inc's (NASDAQ: GH) Q1 FY22 revenues rose 22% Y/Y to $96.1 million, beating the consensus of $95.70 million. Guardant's precision oncology testing revenues grew 32% to $84.1 million, driv...
Guardant Health (GH) Reports Q1 Loss, Lags Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of 1.63% and 0.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health Reports First Quarter 2022 Financial Results
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data se...
Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Ri...
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the availability of Shield™, the company's first blood-based test for the de...
Earnings Preview: Guardant Health (GH) Q1 Earnings Expected to Decline
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Guardant Health to Participate in the BofA Securities 2022 Healthcare Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will be participating in the upcoming BofA Securities 2022 Healthcare ...
This Chart Is Why I'm Not Worried About Guardant Health
The leading innovator in the liquid biopsy space has huge addressable markets ahead of it.
Guardant Health to Report First Quarter Financial Results on May 5, 2022
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2022 after market ...
Guardant Health Presents New Data Showing Blood Test Highly Accurate in Detecting Multiple Cancers at the American As...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new data demonstrating the ability of the company's investigational next-...
2 Top Biotech Stocks to Buy in April
These shares are down significantly from all-time highs, but the businesses have plenty of room for growth.
Guardant Health Announces Partnership with Epic to Streamline Access to Company's Broad Portfolio of Cancer Tests
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with Epic, the nation's most widely used comprehensive heal...
Why Guardant Health Stock Soared Nearly 10% Higher Today
Negativity surrounding the precision oncology company might be overblown.
Looking for Growth? Check Out These 2 Diagnostics Stocks
Hospitals can't do without their products, and demand is rising.
Guardant Health Response to Frivolous and Retaliatory Lawsuit Filed by Illumina
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today provided the following statement regarding a lawsuit filed by Illumina that seeks t...
Guardant Health Receives Regulatory Approval for Guardant360® CDx in Japan
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted ...
Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at the American Association for Cancer Re...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it will present new data from its broad portfolio of blood tests at the A...
Why Guardant Health Jumped Nearly 5% on Tuesday
The health diagnostic company's cancer biomarker test is slowly but surely moving into the mainstream.
Guardant Health Receives Medicare Coverage for Guardant360 TissueNext™ Test
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagn...